EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Fast Itch Relief during Dupilumab Predicts Clinical Efficacy in Bullous Pemphigoid: A Retrospective Cohort Study

Jeivicaa Thevan, Eloi Schmauch, Jakob Nilsson, Carole Florence Guillet, Andrea Boesch, Lukas Krähenbühl, Barbara Meier-Schiesser, Peter Schmid-Grendelmeier, Thomas Kündig, Antonios G A Kolios

Dermatology · 2024

DOI: 10.1159/000540590 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Dermatology, 2024. Verfasst von Jeivicaa Thevan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Hospital Zurich, Zurich, Switzerland, jeivicaa.thevan@uzh.ch. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Pemphigoid, Bullous, Pruritus. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Dupilumab has emerged as a promising treatment option for bullous pemphigoid (BP). Rapid identification of responders could avoid the need for additional immunosuppressive treatments that are associated with increased morbidity and mortality.

Methods

To investigate the course of itch as an early indicator of treatment response, data of 12 BP patients treated with dupilumab at the University Hospital of Zurich were retrospectively evaluated. Disease severity was assessed by bullous pemphigoid disease area index (BPDAI) and pruritus by a numeric rating scale (NRS, 0–10) at baseline; days 1, 3, 14; months 1, 2; and the last follow-up.

Results

A total of 8/12 patients (67%) had complete response, and 4/12 patients (33%) had partial response during dupilumab treatment. Notably, a highly significant reduction of pruritus (p < 0.0001) was observed already on day 1 with further improvement at later time points. Moreover, fast relief of itch could predict treatment response with a significant correlation to clinical response on day 14 (Spearman correlation R 0.70, p value 0.025), with a positive but non-significant trend on day 3 (R 0.63, p value 0.091). Additionally, 92% (11/12 patients) were on dupilumab monotherapy at the last follow-up without any concomitant systemic or topical treatment for BP.

Conclusions

The rapid and significant decline in BP-associated pruritus observed with dupilumab correlated significantly with disease remission. Early evaluation of pruritus response could change how BP is treated in the future and avoid additional immunosuppressive treatment in BP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedPemphigoid, BullousPruritusHumansRetrospective StudiesMaleFemaleAgedMiddle AgedAged, 80 and overTreatment OutcomeSeverity of Illness Index

Stichwörter der Autor:innen

Autoimmune blistering diseasesBullous pemphigoidBullous pemphigoid disease area indexDupilumabPruritus

Substanzen

dupilumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Dermatology, University Hospital Zurich, Zurich, Switzerland, jeivicaa.thevan@uzh.ch.
  • Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
  • A.I. Virtanen Institute, University of Eastern Finland, Kuopio, Finland.
  • Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
  • Department of Immunology, University Hospital Zurich, Zurich, Switzerland.
  • Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.

Zitieren

APA

Thevan, J., Schmauch, E., Nilsson, J., Guillet, C. F., Boesch, A., Krähenbühl, L., Meier-Schiesser, B., Schmid-Grendelmeier, P., Kündig, T., & Kolios, A. G. A. (2024). Fast Itch Relief during Dupilumab Predicts Clinical Efficacy in Bullous Pemphigoid: A Retrospective Cohort Study. Dermatology. https://doi.org/10.1159/000540590

Vancouver

Thevan J, Schmauch E, Nilsson J, Guillet CF, Boesch A, Krähenbühl L, et al. Fast Itch Relief during Dupilumab Predicts Clinical Efficacy in Bullous Pemphigoid: A Retrospective Cohort Study. Dermatology. 2024. doi:10.1159/000540590

BibTeX
@article{Thevan2024,
  author = {Thevan, Jeivicaa and Schmauch, Eloi and Nilsson, Jakob and Guillet, Carole Florence and Boesch, Andrea and Krähenbühl, Lukas and Meier-Schiesser, Barbara and Schmid-Grendelmeier, Peter and Kündig, Thomas and Kolios, Antonios G A},
  title = {Fast Itch Relief during Dupilumab Predicts Clinical Efficacy in Bullous Pemphigoid: A Retrospective Cohort Study},
  journal = {Dermatology},
  year = {2024},
  doi = {10.1159/000540590}
}
Kostenlos starten →